Mechanistic Target of Rapamycin Complex 2
"Mechanistic Target of Rapamycin Complex 2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A multiprotein complex consisting of MTOR KINASE; MLST8 PROTEIN; rapamycin-insensitive companion of mTOR protein (RICTOR PROTEIN); and PRR5 (proline-rich protein 5). Like MTORC1, it also regulates cell growth and proliferation in response to growth factors but may not be as sensitive to nutrient availability and is insensitive to SIROLIMUS. In contrast to MTORC1, it can regulate the ACTIN CYTOSKELETON through RHO GTPASES to promote the formation of STRESS FIBERS. The mTORC2 complex also plays a critical role in AKT1 PROTEIN KINASE phosphorylation and activation.
Descriptor ID |
D000076225
|
MeSH Number(s) |
D05.500.356 D08.811.913.696.620.682.700.931.750 D12.776.476.925.750
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Mechanistic Target of Rapamycin Complex 2".
Below are MeSH descriptors whose meaning is more specific than "Mechanistic Target of Rapamycin Complex 2".
This graph shows the total number of publications written about "Mechanistic Target of Rapamycin Complex 2" by people in this website by year, and whether "Mechanistic Target of Rapamycin Complex 2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2017 | 1 | 2 | 3 |
2018 | 2 | 2 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Mechanistic Target of Rapamycin Complex 2" by people in Profiles.
-
Coronavirus disease 2019 (COVID-19), human erythrocytes and the PKC-alpha/-beta inhibitor chelerythrine -possible therapeutic implication. Cell Cycle. 2020 12; 19(24):3399-3405.
-
Inhibition of RhoA and mTORC2/Rictor by Fingolimod (FTY720) induces p21-activated kinase 1, PAK-1 and amplifies podosomes in mouse peritoneal macrophages. Immunobiology. 2018 11; 223(11):634-647.
-
The Kinase Complex mTOR Complex 2 Promotes the Follicular Migration and Functional Maturation of Differentiated Follicular Helper CD4+ T Cells During Viral Infection. Front Immunol. 2018; 9:1127.
-
First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13). Eur J Cancer. 2018 06; 96:6-16.
-
MTOR inhibitor-based combination therapies for pancreatic cancer. Br J Cancer. 2018 02 06; 118(3):366-377.
-
Influenza virus differentially activates mTORC1 and mTORC2 signaling to maximize late stage replication. PLoS Pathog. 2017 Sep; 13(9):e1006635.
-
Two distinct mTORC2-dependent pathways converge on Rac1 to drive breast cancer metastasis. Breast Cancer Res. 2017 Jun 30; 19(1):74.
-
TRAF2 and OTUD7B govern a ubiquitin-dependent switch that regulates mTORC2 signalling. Nature. 2017 05 18; 545(7654):365-369.